By Helen Borel, R.N.,Ph.D.
Sufferers of psoriasis – a chronic, very uncomfortable skin condition that produces dry, unsightly plaques and leads to embarrassment or social withdrawal – now can anticipate a new topical medication (a drug for the skin surface, e.g. lotions, ointments) that has so far shown thorough clearing of psoriatic plaques in sixty percent of those tested and partial clearing in others.
New Trials - Currently in further clinical trials under the aegis of Manhattan Pharmaceuticals, its developer, PTH (1-34) will now be compared for efficacy and safety in 54 additional patients during 8 weeks of treatment – some receiving the active product; others the topical formulation minus the PTH (1-34).
How It Works - Normal skin cells evolve from lower to upper surfaces over a period of a month; while psoriatic skin cells go through this cycle within only three or four days. So this disease of excessive skin-cell growth, believed exacerbated by abnormal immune system activity, motivated Manhattan Pharmaceuticals’ scientists to try making psoriatic cells behave like normal skin cells.
Normally the substance PTHrp modulates skin-cell growth. And the researchers believe that PTH (1-34) simulates this natural protein’s action so that skin-cell growth is slowed down to more normal rates.
For more than four million Americans struggling with psoriasis, PTH (1-34) appears promising.
Here’s a link to this pioneering company—> http://www.manhattanpharma.com/
(c) Copyright 2007 to 2015 Helen Borel. All rights reserved.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment